Caution is advised, however, in light of evidence that KRAS inhibition using CRISPR/Cas9–mediated gene editing of oncogenic KRAS may be dispensable for a subset of pancreatic cancer cell clones that are able to survive without it (22). This evidence concerns the gene KRAS and familial pancreatic carcinoma.